Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
554 Leser
Artikel bewerten:
(2)

Arix Bioscience PLC: Corporate update from portfolio company Harpoon Therapeutics

DJ Corporate update from portfolio company Harpoon Therapeutics

Arix Bioscience PLC (ARIX) Corporate update from portfolio company Harpoon Therapeutics 14-March-2022 / 11:32 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

PRESS RELEASE

Arix Bioscience plc

Corporate update from portfolio company Harpoon Therapeutics

LONDON, 14 March 2022: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, notes the recent announcement from Harpoon Therapeutics, Inc. (Nasdaq: HARP) of its financial results for the fourth quarter and full year of 2021, in which the company provided a corporate update.

Following a thorough analysis of its HPN424 data, including clinical results to date, the company decided to discontinue the phase 1/2 dose escalation study for HPN424 in patients with metastatic castration-resistant prostate cancer. The discontinuation will allow Harpoon to concentrate on HNP328, in development for tumours associated with delta like ligand 3 (DLL3) expression, and HPN 217 for BCMA.

Earlier in March, Harpoon announced the granting of Orphan Drug Designation for HPN328 in small cell lung cancer and Fast Track designation for HPN2178 in relapsed, refractory multiple myeloma. Studies to determine the recommended phase 2 dose for both candidates are expected to complete this year.

The full text of the Harpoon announcement can be accessed here.

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil

+44 (0)20 7250 1446

arix@powerscourt-group.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

-----------------------------------------------------------------------------------------------------------------------

ISIN:      GB00BD045071 
Category Code: PFU 
TIDM:      ARIX 
LEI Code:    213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:  148920 
EQS News ID:  1301829 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1301829&application_name=news

(END) Dow Jones Newswires

March 14, 2022 07:32 ET (11:32 GMT)

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2022 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.